Among patients with T2D and DPN, some with nonpainful DPN developed neuropathic pain over a 5-year period while others with painful DPN experienced relief.

Alnylam stock jumps 15% after a surprise Q2 profit, driven by soaring Amvuttra sales and raised 2025 revenue guidance.

Copyright © 2025 European Medical Group LTD trading as European Medical Journal. All rights reserved. European Medical ...

Q2 2025 Earnings Call Transcript July 31, 2025 Alnylam Pharmaceuticals, Inc. beats earnings expectations. Reported EPS is ...

Ulnar sensory-motor amplitude ratio: a new tool to differentiate ganglionopathy from polyneuropathy Razão de amplitude sensitivo-motora ulnar: novo parâmetro para diferenciar ganglionopatia de ...

Despite battling drugs from BridgeBio and Pfizer, Amvuttra beat Wall Street expectations with results CEO Yvonne Greenstreet ...

Background The occurrence of ataxic polyneuropathy in an endemic area in south west Nigeria has been attributed to exposure to cyanide from cassava foods. However, it has been shown that the ...

In its first commercial quarter for ATTR-cardiomyopathy, Alnylam’s Amvuttra reached roughly 1,400 patients and made more than $490 million.

AIMS To obtain precise information on ocular manifestations of familial amyloidotic polyneuropathy (FAP) type I, the incidence of five main ocular manifestations—abnormal conjunctival vessels (ACV), ...

Timberlake said the diagnosis helped explain the persistent fatigue, nerve pain, and unexplained illness he had been ...

Baron Funds, an investment management company, released its “Baron Health Care Fund” second-quarter 2025 investor letter. A ...

Background: Polyneuropathy with IgM monoclonal gammopathy can be a disabling disorder necessitating treatment. Methods: In a prospective open label trial, 17 patients with disabling IgM MGUS ...